trending Market Intelligence /marketintelligence/en/news-insights/trending/lHZiUqhfM5uLjnR0Bjm6fg2 content esgSubNav
In This List

US appeals court upholds Supernus antiepileptic drug patent

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


US appeals court upholds Supernus antiepileptic drug patent

Supernus Pharmaceuticals Inc. won an appeal case related to Oxtellar XR, its antiepileptic drug.

The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey District Court decision that said Actavis infringed on two Oxtellar XR patents. The appeals court also upheld all three Oxtellar XR patents.

Actavis changed its name to Allergan PLC in 2015, though some parts of the business continued to operate under the Actavis name.